Ethosuximide
As of the edition of 20 October 2026, Ethosuximide is a small molecule: marketed, first approved in 1960 (CA); acts on CACNA1G, CACNA1H and CACNA1I.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1988
- Kind
- Small molecule
- Brand name
- Zarontin
- First approved
- 31 December 1960 (CA)
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- ESSENTIAL PHARMA (M) (MALTE); 4 holders in all
- Registered trials
- 9, 2 stopped early
- Disease areas
- Nervous system; Digestive system; Cancer; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 6 | 3 | 0 | 2 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 9 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant |